Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy-Reference-Cited by-同舟云学术

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Published:2013-06-27 Issue:26 Volume:121 Page:5154-5157
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Teachey David T.¹²,Rheingold Susan R.¹²,Maude Shannon L.¹²,Zugmaier Gerhard³,Barrett David M.¹²,Seif Alix E.¹²,Nichols Kim E.¹²,Suppa Erica K.⁴,Kalos Michael⁴,Berg Robert A.⁵⁶,Fitzgerald Julie C.⁵⁶,Aplenc Richard¹²,Gore Lia⁷,Grupp Stephan A.¹²

Affiliation:

1. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA;

2. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

3. Amgen Research (Munich) GmBH, Munich, Germany;

4. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

5. Division of Critical Care, Children's Hospital of Philadelphia, Philadelphia, PA;

6. Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; and

7. Department of Pediatrics, University of Colorado Cancer Center, Aurora, CO

Abstract

Key Points Cytokine release syndrome caused by T cell-directed therapies may be driven by abnormal macrophage activation and hemophagocytic syndrome. Cytokine-directed therapy can be effective against life-threatening cytokine release syndrome.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/26/5154/1367295/5154.pdf

Reference20 articles.

1. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.;Löffler;Blood,2000

2. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.;Bargou;Science,2008

3. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.;Topp;Blood,2012

Cited by 509 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease;Frontiers in Immunology;2024-02-06

2. Hemophagocytic lymphohistiocytosis after solid organ transplantation: A challenge for clinicians;Transplant Immunology;2024-02

3. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting;Journal of Comparative Effectiveness Research;2024-02

4. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment;Blood Advances;2024-01-23

5. Hemophagocytic Lymphohistiocytosis;Reference Module in Biomedical Sciences;2024